NasdaqGM:FLXN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.

Share Price & News

How has Flexion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FLXN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.0%

FLXN

-2.2%

US Biotechs

-0.8%

US Market


1 Year Return

-20.8%

FLXN

35.6%

US Biotechs

13.8%

US Market

Return vs Industry: FLXN underperformed the US Biotechs industry which returned 35.6% over the past year.

Return vs Market: FLXN underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

FLXNIndustryMarket
7 Day-8.0%-2.2%-0.8%
30 Day-4.1%-0.08%-5.0%
90 Day-13.1%-1.7%10.1%
1 Year-20.8%-20.8%38.0%35.6%16.4%13.8%
3 Year-54.4%-54.4%15.6%10.0%36.9%27.8%
5 Year-24.0%-24.0%19.3%11.0%85.0%64.2%

Price Volatility Vs. Market

How volatile is Flexion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Flexion Therapeutics undervalued compared to its fair value and its price relative to the market?

32.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FLXN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FLXN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FLXN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FLXN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FLXN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FLXN is overvalued based on its PB Ratio (32.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Flexion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

69.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLXN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: FLXN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FLXN's is expected to become profitable in the next 3 years.

Revenue vs Market: FLXN's revenue (38.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: FLXN's revenue (38.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FLXN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Flexion Therapeutics performed over the past 5 years?

-25.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLXN is currently unprofitable.

Growing Profit Margin: FLXN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FLXN is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare FLXN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FLXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: FLXN has a negative Return on Equity (-854.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Flexion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FLXN's short term assets ($246.6M) exceed its short term liabilities ($37.4M).

Long Term Liabilities: FLXN's short term assets ($246.6M) exceed its long term liabilities ($217.9M).


Debt to Equity History and Analysis

Debt Level: FLXN's debt to equity ratio (1322.8%) is considered high.

Reducing Debt: FLXN's debt to equity ratio has increased from 0.3% to 1322.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FLXN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FLXN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.5% each year


Next Steps

Dividend

What is Flexion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FLXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLXN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLXN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLXN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Mike Clayman (68 yo)

13.67yrs

Tenure

US$3,777,360

Compensation

Dr. Michael D. Clayman, also known as Mike, M.D., Co-Founded Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc) in 2007 and has been its Chief Executive Officer and President since 20 ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Clayman
Co-Founder13.67yrsUS$3.78m0.86%
$ 4.7m
Neil Bodick
Consultantno dataUS$1.36m0.14%
$ 762.1k
Scott Kelley
Chief Medical Officer2.75yrsUS$1.33m0.24%
$ 1.3m
David Arkowitz
Chief Financial Officer2.33yrsUS$3.21m0.32%
$ 1.7m
Scott Young
VP of Corporate Communications & Investor Relationsno datano datano data
Carolyn Scimemi
VP, Legal Affairs & Chief Compliance Officer4yrsno datano data
Mark Levine
General Counsel & Secretary3.25yrsUS$1.21m0.23%
$ 1.3m
John Magee
Vice President of Sales4yrsno datano data
Christina Willwerth
Chief Strategy Officer4yrsno data0.25%
$ 1.3m
Kerry Wentworth
Chief Regulatory Officer4.83yrsno data0.26%
$ 1.4m
Adam Muzikant
Senior Vice President of Business Development1.67yrsno datano data
Melissa Layman
Chief Commercial Officer0.50yrno datano data

3.6yrs

Average Tenure

59yo

Average Age

Experienced Management: FLXN's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Clayman
Co-Founder13.67yrsUS$3.78m0.86%
$ 4.7m
Samuel Colella
Independent Director12.67yrsUS$153.68k0.15%
$ 835.7k
Alan Milinazzo
Independent Director9.67yrsUS$151.18k0.047%
$ 252.9k
Patrick Mahaffy
Independent Chairman11.67yrsUS$206.31k0.063%
$ 339.7k
C. Merrifield
Independent Director6.25yrsUS$146.18k0.020%
$ 110.2k
Heath Lukatch
Independent Director7.75yrsno data0%
$ 0
Scott Canute
Independent Director5.5yrsUS$141.18k0%
$ 0
Mark Stejbach
Independent Director4yrsUS$146.18k0.0074%
$ 40.0k
Sandesh Mahatme
Independent Director6.17yrsUS$156.18k0%
$ 0
Elizabeth Kwo
Non-Employee Director0.083yrno datano data

7.0yrs

Average Tenure

59yo

Average Age

Experienced Board: FLXN's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.4%.


Top Shareholders

Company Information

Flexion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Flexion Therapeutics, Inc.
  • Ticker: FLXN
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$543.318m
  • Shares outstanding: 49.30m
  • Website: https://www.flexiontherapeutics.com

Number of Employees


Location

  • Flexion Therapeutics, Inc.
  • 10 Mall Road
  • Suite 301
  • Burlington
  • Massachusetts
  • 1803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLXNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014

Biography

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 06:37
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.